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Methods:  The effect of oral administration of test solutions (water, 0.5M or 0.05M
GABA, 1% lidocaine) was investigated for the amelioration of pain and sensitivity
induced by application of capsaicin (1%, 2 minutes) to the tongue of thirty healthy male
and female subjects in this 4-session, randomized, placebo-controlled, double-blinded,
cross-over study.  Intraoral quantitative sensory testing was used to assess cold
(CDT), warm (WDT) and mechanical (MDT) detection thresholds as well as mechanical
(MPT) and heat (HPT) pain thresholds. Capsaicin-induced pain intensity was
continuously rated on a 0-10 electronic visual analogue scale (VAS). The area under
the VAS curve (VASAUC) after rinsing was calculated for each solution.
Results:  Capsaicin application on the tongue evoked burning pain with a peak of
4.8/10, and significantly increased CDT and MDT while significantly decreasing WDT,
HPT, and MPT. The VASAUC was significantly smaller after oral rinse with 0.05M
GABA, 0.5M GABA, and 1% lidocaine than after oral rinse with water. Rinse with 0.5M
or 0.05M GABA were similarly effective in decreasing VASAUC. Rinsing with either 1%
lidocaine, 0.5M or 0.05M GABA also significantly attenuated the effects of capsaicin on
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Conclusions  Capsaicin-induced burning tongue pain and decreases in WDT and HPT
can be ameliorated by rinsing the mouth with lidocaine and GABA solutions.
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Abstract (242/250) 
Background:  In burning mouth patients, analgesia after oral administration of 
clonazepam may result from modulation of peripheral -aminobutyric acid (GABA ) 
receptors. 
Methods:  The effect of oral administration of test solutions (water, 0.5M or 0.05M 
GABA, 1% lidocaine) was investigated for the amelioration of pain and sensitivity 
induced by application of capsaicin (1%, 2 minutes) to the tongue of thirty healthy 
male and female subjects in this 4-session, randomized, placebo-controlled, 
double-blinded, cross-over study.  Intraoral quantitative sensory testing was used to 
assess cold (CDT), warm (WDT) and mechanical (MDT) detection thresholds as well 
as mechanical (MPT) and heat (HPT) pain thresholds. Capsaicin-induced pain 
intensity was continuously rated on a 0-10 electronic visual analogue scale (VAS). 
The area under the VAS curve (VASAUC) after rinsing was calculated for each 
solution.   
Results:  Capsaicin application on the tongue evoked burning pain with a peak of 
4.8/10, and significantly increased CDT and MDT while significantly decreasing WDT, 
HPT, and MPT. The VASAUC was significantly smaller after oral rinse with 0.05M 
GABA, 0.5M GABA, and 1% lidocaine than after oral rinse with water. Rinse with 0.5M 
or 0.05M GABA were similarly effective in decreasing VASAUC. Rinsing with either 1% 
lidocaine, 0.5M or 0.05M GABA also significantly attenuated the effects of capsaicin 
on WDT and HPT in a treatment independent manner. There were no sex-related 
differences in these effects of GABA.   
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Conclusions  Capsaicin-induced burning tongue pain and decreases in WDT and 
HPT can be ameliorated by rinsing the mouth with lidocaine and GABA solutions.   
 
 
Significance: (40 words): Rinsing the mouth with an oral GABA containing solution 
ameliorated burning pain and increased heat sensitivity produced by application of 
capsaicin to the tongue. This finding suggests that GABA can act as a local analgesic 
agent in the oral cavity. 
 
Keywords:  Analgesia; Burning mouth syndrome; Orofacial; GABA; Tongue; 
Quantitative sensory testing, 
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Introduction 
Burning mouth syndrome (BMS) is a chronic intraoral pain condition characterized by 
symptoms of “burning-like” pain most commonly experienced on the anterior of the 
tongue (Grushka 1987; Svensson et al., 1993; Tammiala-Salonen et al., 1993; 
Vanderploeg et al., 1987).  It has been proposed that BMS is a type of peripheral 
deafferentiation neuropathy (Forssell et al., 2002).  On examination, many BMS 
patients report a loss of thermal detection sensitivity over the affected area in the 
tongue and oral mucosa, as well as altered taste sensations (Kolkka-Palomaa et al., 
2015).   Tongue biopsies from BMS patients when compared with healthy controls 
have a significantly lower density of epithelial nerve fibers (Lauria et al., 2005).  
Nerve fiber changes suggestive of axonal degeneration and injury, such as increased 
levels of nerve growth factor and expression of TRPV1 and P2X3 receptors, appear to 
be associated with the decreased density of tongue epithelial nerve fibers in these 
patients (Kolkka-Palomaa et al., 2015; Yilmaz et al., 2007).  The source of nerve 
injury in BMS is not known, but one speculated cause is repeated thermal injury to the 
mouth from hot food and beverages (Kolkka-Palomaa et al., 2015).   
Human experimental pain studies have applied capsaicin to the tongue or gingiva 
to produce burning pain in the oral cavity (Albin et al., 2008; Baad-Hansen et al., 2007; 
Baad-Hansen et al., 2003; Boudreau et al., 2009; Mo et al., 2015; Ngom et al., 2001). 
Application of 1-5% capsaicin causes burning pain which peaks after a few minutes, 
and then declines (Baad-Hansen et al., 2007; Baad-Hansen et al., 2003; Lu et al., 
2013).  In addition to burning pain, capsaicin application increases heat pain 
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sensitivity, but reduces sensitivity to innocuous and noxious mechanical stimuli as well 
as mechanical windup induced pain (Baad-Hansen et al., 2007; Baad-Hansen et al., 
2003; Lu et al., 2013).  Thus, topical application of capsaicin to the tongue can 
replicate some of the pain and pain sensitivity features of BMS. 
Conservative medical treatment aimed at symptom resolution is the normal 
therapeutic approach for BMS.  Unfortunately, BMS symptoms have proven quite 
resistant to pharmacotherapy.   Some BMS patients report a significant symptomatic 
improvement in their pain after sucking, without swallowing, a 1 mg tablet of the 
benzodiazepine clonazepam three times a day (Gremeau-Richard et al., 2004).  
Benzodiazepines are anxiolytic drugs which increase the ability of -amino-butyric 
acid (GABA) to open the GABAA receptor.  In some pre-clinical pain models, 
activation of peripheral GABAA receptors in orofacial tissues appears to exert 
anti-nociceptive actions (Cai et al., 2001; Cairns et al., 2001; Cairns et al., 1999).   
These findings suggest that topical application of benzodiazepines to the oral mucosa 
may be effective in decreasing pain in BMS through a local action on peripheral 
GABAA receptors to decrease the excitability of nociceptors.  The present study was 
conducted to determine if oral administration of GABA containing solutions could 
reduce pain and sensitivity induced by local application of capsaicin to the tongue of 
healthy human subjects. 
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Methods 
Subjects 
Thirty healthy subjects (19 men and 11 women, mean age 26 ± 3) participated in this 
study conducted at Aalborg University.   Subjects were recruited between June and 
December, 2016.  All subjects were free from ongoing pain. Exclusion criteria 
included pregnancy, regular use of psychiatric, analgesic or other medications that 
might influence pain response, previous neurologic, musculoskeletal or mental 
illnesses, or a lack of ability to cooperate. The study was approved by the Scientific 
Ethics Committee for the North Jutland Region of Denmark (reference no. 
N-20160037).  Written informed consent was obtained from all participants.  This 
trial was registered at ClinicalTrials.gov (NCT02928328). 
 
Experimental protocol 
This study employed a randomized, placebo-controlled, double-blinded, cross-over 
study design.  A computerized randomization table was used to assign treatments 
(KW), and the examiner (YZ) who undertook the intraoral quantitative sensory testing 
(QST) was unaware of the treatment subjects received.  Each subject was enrolled 
by either KW or YZ, and participated in 4 experimental sessions (Figure 1).  
Sessions were a minimum of 3 days apart, and subjects were requested avoid eating 
chili peppers or garlic for at least 24 hours prior to the experimental session.  
At the beginning of each session, baseline intraoral QST on the tip of the tongue 
was carried out (Base).  Then, the subjects received topical application of 1% 
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capsaicin cream (Aalborg Hospital Pharmacy, Aalborg Denmark) to the tongue 
dorsum for 2 minutes (Figure 1)(Boudreau et al., 2009).  A standardised 
tongue-shaped piece of plastic film with a circular cut out of it that was approximately 
2 cm2 was then placed on the surface of tongue (~1.5 cm from the tip) to permit 
uniform application of capsaicin to the tongue. After application of capsaicin cream 
(1%, 1 g, Aalborg hospital pharmacy), another piece of tongue-shaped plastic film 
was placed on top the capsaicin to avoid its spreading.   Upon application of the 
capsaicin cream, subjects were instructed to rate their oral pain on an electronic 0-10 
cm Visual Analogue Scale (VAS, “0” indicating no pain, and “10” indicating the worst 
pain imaginable; Figure 1.  At the end of the 2-minute application, capsaicin was 
removed with a cotton ball, and intraoral QST was performed again (CAP; Figure 1). 
Subjects were then instructed to rinse their mouths with 20 ml of solution containing 
one of 2 concentrations of GABA (0.05 or 0.5 M), 1 % lidocaine (positive control) or 
distilled water (vehicle control) for 2 minutes, after which they spit the solution out.  
The clear solutions containing the treatments, labelled A, B, C or D, were stored in the 
fridge prior to use and given based the order in the randomization table.  After 
spitting the solution out, oral QST was assessed (Rinse), and then reassessed after a 
10-minute break (Post).  
 
Intraoral QST 
Tests included tongue cold and warm detection thresholds, cold and heat pain 
thresholds, mechanical detection thresholds and mechanical pain thresholds.  
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Thermal tests were performed using a computerized thermal stimulator (MEDOC 
TSA-2001 apparatus, Medoc Ltd, Ramat-Yishai, Israel). The contact area of the 
intra-oral thermode was 36 mm2. Cold and warm detection thresholds (CDT, WDT) 
were measured first, and were followed by cold and heat pain thresholds (HPT). The 
mean threshold of 3 consecutive measurements was calculated for each time period.  
During each thermal assessment, the temperature of the thermode was initially 37°C 
and was decreased or increased at a rate of 1°C/s to a lower or upper limit of 0°C and 
50°, respectively.  The participants were instructed to press a button on a computer 
mouse as soon as they detected the appropriate thermal sensation (Mo et al., 2015; 
Svensson et al., 2011).   
MDT and MPT were measured using a “method of limits” technique 
(Baad-Hansen et al., 2003).  Standardized Semmes-Weinstein monofilaments 
(North Coast Medical, Canada) with 20 different diameters were used to measure 
MDT. To prevent filament slippage, intra-oral examination sites were dried with gauze 
before testing [14,15]. 
To detect the mechanical pain threshold (MPT), weighted pinprick stimuli 
delivered with a custom-made set of seven pinprick stimulators (Aalborg University, 
Denmark) were used (Mo et al., 2015; Suzuki et al., 2016).  Each stimulator had a 
flat contact surface of 0.2 mm that exerted forces of 8-512 mN. All pinprick tests were 
made with the stimulator perpendicular to the examination site and in a vertical 
position with a contact time of 1 second. Five threshold measurements were made, 
applying a series of ascending and descending stimulus intensities. Threshold was 
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determined by calculating the geometric mean of these five measurements. 
 
Oral rinse solutions 
GABA powder (Now Foods, Sparks, Nevada, USA) was dissolved in deionized water, 
and adjusted to a concentration of either 51.5 mg/ml (0.5 M), or 5.2 mg/ml (0.05 M).  
Injectable lidocaine (1% , Lidocaine, Copenhagen, Denmark) solution was used as 
the positive control, as it has been shown to significantly reduce capsaicin induced 
burning pain on the tongue (Gottrup et al., 2000; Ngom et al., 2001). Deionized water 
was used as a vehicle control. 
 
Data analysis 
The sample size was estimated based on a minimal relevant difference in VAS 
between treatments of 25% (primary outcome measurement), a conservative 
estimate of the intra-individual variation in the VAS of 30% and a risk of type I and type 
II errors of 5% and 20%, respectively.  This estimation indicated that 24 subjects 
would be required.  However, to compensate for a possible 20% drop out rate, we 
recruited 30 subjects for the study.  
 The area under the VAS curve was calculated (VASAUC) for i) CAP (0-10 min), 
and ii) Rinse (12-30 min) (Figure 1B).  A one-way repeated measures ANOVA on 
ranks was used to determine if there were significant intersessional differences in the 
response to capsaicin and to assess whether there were significant differences 
between the treatments.  Tukey tests were used for post-hoc analysis.  Sex-related 
10 
 
differences for each treatment were assessed with Mann-Whitney rank sum tests. 
Two way repeated measures ANOVAs (factors: time, treatment) were also used to 
assess for significant differences in the QST parameters (secondary outcome 
measures).  Where QST data was not normally distributed, log transformation was 
applied. Student-Neuman-Keuls tests were employed for post-hoc comparisons.   A 
P value <0.05 was considered significant.   
 
 
 
Results 
Capsaicin-evoked pain  
All 30 subjects completed the study.  Capsaicin application to the tongue elicited a 
mild burning pain with a peak of 4.8 ± 0.3 that was not significantly different in men 
and women.  A significant intersessional difference in the VASAUC for capsaicin was 
found. Post-hoc testing indicated that the VASAUC for capsaicin alone was 
significantly greater in the lidocaine session than in the water session (Figure 2A).  
To compensate, the VASAUC for the post rinse period was normalized to the 
VASAUC for capsaicin in each session (Figure 2B).  Normalized VASAUC was 
significantly decreased, compared to water , when either concentration of GABA or 
lidocaine 1% were used in the rinse.  Lidocaine reduced the normalized VASAUC to 
a significantly greater amount than either concentration of GABA .  There was no 
significant concentration-related difference in the analgesic effect of GABA .  There 
were no significant sex-related differences in response to any of the treatments. 
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Thermal Parameters 
CDT was significantly lowered (less sensitive) by capsaicin treatment. There was no 
significant effect of treatment on capsaicin-induced lowering of the CDT (Figure 3A). 
Mean baseline CDT (women: 31.8 ± 0.7 C, men: 30.7 ± 0.3 C) was not significantly 
different between men and women.  
Although cold pain threshold was also assessed, most subjects did not report 
pain from cold stimulation of the tongue and thus these data could not be assessed 
further.  
 WDT was significantly decreased (more sensitive) by CAP in all sessions and 
significantly increased (less sensitive) by rinsing the mouth in all sessions.  Rinsing 
with GABA (0.05 or 0.5M) or lidocaine 1% resulted in a significantly greater increase 
in WDT compared to rinsing with water (Figure 3B).   Mean baseline WDT (women: 
41.5 ± 0.8 C, men: 42.3 ± 0.4 C) was not significantly different between men and 
women. 
HPT was significantly decreased (more sensitive) by capsaicin in all sessions and 
significantly increased (less sensitive) by rinsing the mouth in all sessions.  Rinsing 
with GABA (0.05 or 0.5M) or lidocaine 1% resulted in a significantly greater increase 
in HPT compared to rinsing with water.  Mean baseline HPT (women: 44.4 ± 0.8 C, 
men: 46.7 ± 0.4 C) was not significantly different between men and women.  
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Mechanical Parameters 
MDT was significantly increased (less sensitive) by capsaicin treatment in all sessions.  
There was no significant effect of treatment on capsaicin-induced increase of the MDT 
(Figure 4A).  Mean baseline MDT (women: 0.59 ± 0.28 g, men: 0.44 ± 0.09 g) was 
not significantly different between men and women, and there were no sex-related 
differences in the effect of the treatments.    
MPT was significantly decreased (more sensitive) by capsaicin treatment in all 
sessions, and this effect was significantly reversed by rinsing the mouth with all of the 
treatment solutions.  There was no difference between the treatments (Figure 4B).  
Mean baseline MPT (women: 81 ± 8 g, men: 82 ± 8 g) was not significantly different 
between men and women. 
There was no significant difference between men and women in any of the QST 
parameters.  
 
Blinding 
At the end of each session, subjects were asked to indicate which of the 4 possible 
treatments they thought they had received.  For water, GABA 0.05M and GABA 0.5M, 
47%, 30% and 27% of subjects guessed correctly.  This is not a significantly different 
frequency of response than would have been expected simply by chance (Fisher 
exact test).  However, when given lidocaine, 80% of subjects guessed correctly what 
was in the oral rinse.  This result suggests that most subjects, not surprisingly, were 
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able to detect the effects of this local anesthetic when it was administered in the rinse 
solution. 
 
Adverse Effects 
Potential adverse effects of orally consumed GABA may include drowsiness as well 
as a short term increase in heart rate and shortness of breath.  Sensations of tingling, 
itching, tickling in the neck, face and limbs have also been reported. Subjects in the 
present study did not report any of these effects after rinsing their mouths with GABA 
solutions.  
 
Discussion and Conclusions 
The present study found that rinsing with either GABA 0.05 M or GABA 0.5 M solution 
was significantly more effective than water in reducing the burning pain produced by 
topical application of capsaicin to the tongue.  In addition to burning pain, capsaicin 
application to the tongue increased mechanical detection threshold (less sensitive), 
but reduced mechanical pain as well as warm detection and heat pain thresholds 
(more sensitive).  Compared to water, GABA containing rinse solutions were also 
significantly more effective in ameliorating the lowered warmth detection and heat 
pain thresholds produced by topical capsaicin.  These results suggest that GABA 
containing solutions exert a peripheral localised analgesic effect in this model of 
burning mouth pain  
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Capsaicin induced burning mouth pain 
A number of studies have previously applied capsaicin to the tongue or gingiva to 
produce burning pain for a period of up to 25 minutes (Albin et al., 2008; 
Baad-Hansen et al., 2007; Baad-Hansen et al., 2003; Boudreau et al., 2009; Mo et al., 
2015; Ngom et al., 2001).  In addition to pain, capsaicin application was reported to 
increase heat pain sensitivity, but reduced sensitivity to innocuous and noxious 
mechanical stimuli as well as mechanical windup induced pain (Albin et al., 2008; 
Baad-Hansen et al., 2007; Baad-Hansen et al., 2003; Lu et al., 2013).   The effect of 
capsaicin on cold pain is variable (Albin et al., 2008).  Thus, consistent with our 
findings, topical application of capsaicin to the oral cavity appears to increase 
sensitivity to heat and decrease sensitivity to innocuous mechanical stimulation.  In 
contrast, BMS patients often exhibit a loss of cold and heat pain detection sensitivity 
on the tongue without change in mechanical pain detection thresholds controls (Mo et 
al., 2015).  Thus, while capsaicin application to the tongue can replicate the burning 
pain reported by BMS patients, it does not produce similar effects on thermal and 
mechanical sensitivity.  
 
GABA acts on peripheral GABAA receptors 
Injection of GABA into the rat temporomandibular joint has previously been 
shown to exert analgesic-like actions through activation of the peripheral GABAA 
receptor (Cai et al., 2001; Cairns et al., 1999).  More recently, GABAA receptors have 
been shown to be expressed by a majority of putative nociceptors that innervate the 
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epithelium of the rat tongue (Tan et al., 2014).  Application of 0.5 M GABA or the 
selective GABAA receptor agonist muscimol to the rat tongue attenuated the 
mechanical sensitization of polymodal nociceptors that occurred after application of 
hot (60oC) water to the tongue (Tan et al., 2014).  In the present study, the same 
concentration of GABA was able to attenuate the sensitizing effect of capsaicin on 
tongue warmth detection and heat pain thresholds.  Taken together, these findings 
suggest that topical application of benzodiazepines to the oral mucosa, which has 
been shown to reduce pain in patients with BMS [10-12], could be efficacious due to a 
local action on peripheral GABAA receptors. 
 
Treatment of burning mouth pain 
Available evidence supports the long term treatment effectiveness of topical 
clonazepam and low concentration capsaicin oral rinses for BMS (Kisely et al., 2016; 
Liu et al., 2017; McMillan et al., 2016).  Unfortunately, many patients receiving 
capsaicin oral rinses develop dyspepsia that causes them to withdraw from treatment, 
which limits the usefulness of this approach (Kisely et al., 2016).  Orally restricted 
administration clonazepam has few reported side effects (Kisely et al., 2016; Liu et al., 
2017; McMillan et al., 2016).  Systemically administered clonazepam, which does 
cause some level of drowsiness or sedation, may also not be as effective for pain in 
BMS as topical clonazepam (Kisely et al., 2016; McMillan et al., 2016).   However, in 
studies that investigated local anesthetics, a minimal and clinically negligible effect on 
pain in BMS patients was found (Kisely et al., 2016; Liu et al., 2017).  This contrasts 
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with our finding that lidocaine rinse significantly reduced acute capsaicin-induced 
burning mouth pain, and was in fact significantly more effective than GABA containing 
solutions in this effect.  Lidocaine is a local anesthetic that has been previously 
shown to effectively block the burning pain induced by capsaicin (Gottrup et al., 2000; 
Ngom et al., 2001).  However, it is important to point out that most subjects given 
lidocaine rinse were able to correctly identify this treatment due to its recognizable 
numbing effect, and that this knowledge may have biased their pain ratings.  
Nevertheless differences in the response characteristics of healthy individuals given 
capsaicin to induce burning mouth pain in this study and patients diagnosed with BMS 
to local application of lidocaine indicate that caution should be exercised in attempting 
a direct translation of the results into clinical treatment.  
 GABA is currently sold as a health food supplement in the European Union and 
North America.  Although GABA is an inhibitory amino acid, it does not appear to 
effectively cross the adult human blood brain barrier, and thus little, if any, orally 
ingested GABA likely makes it into the brain (Boonstra et al., 2015).   There are no 
reports of major side effects after daily consumption of oral GABA up to 3 g (Goldberg 
2010; Powers et al., 2008).  Nevertheless, to minimize the potential for healthy 
subjects in the present study to have significant systemic exposure to GABA, they 
were further required to expectorate oral solutions after rinsing.  Subjects receiving 
GABA in the current study did not report feeling symptoms, such as drowsiness or 
dizziness, suggestive of a systemic effect of a central nervous system depressant.  
Further, unlike lidocaine, subjects did not report believing that they had received 
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GABA more often than expected by chance in the present study.  This is interpreted 
as further evidence that oral rinses with GABA containing solutions act locally within 
the oral cavity to exert their analgesic effect. 
 
Limitations  
A potential limitation of this study was that stimuli were only applied to the tip of 
the tongue.  However, thermal thresholds (WDT, HPT, CDT) from the middle anterior 
dorsal surface of the tongue are comparable with those of the present study, despite 
differences in innervation density (Kaplan et al., 2011).  Nevertheless, it is unclear 
whether the local analgesic effects of GABA would extend to the rest of the tongue or 
oral cavity.   
As discussed previously, capsaicin-induced buring tongue pain does not replicate 
all of the symptoms of burning mouth syndrome.  In addition to those mentionied, 
burning mouth syndrome can be associated with metabolic changes (e.g. diabetes) 
and mood alterations (e.g. anxiety, depression) in a subset of patients, which cannot 
be replicated by acute administration of capsaicin (Arap et al., 2010; de Souza et al., 
2012; Moore et al., 2007; Penza et al., 2010).   Indeed, the acute nature of the 
burning pain makes this model very different from the chronic ongoing pain that is 
characteristic of many burning mouth sufferers.   
 
 
 
18 
 
Conclusion 
It is concluded that rinsing the mouth with GABA solution resulted in concentration 
independent decreases capsaicin-induced burning pain in the mouth and some of its 
associated sensory changes on the tongue in healthy subjects, which suggests that 
GABA can act as a local analgesic agent in the oral cavity.  Future research is 
required to determine whether use of GABA oral solutions might be effective in the 
treatment of BMS-related burning pain. 
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Figure Legends: 
Figure 1:  The drawing illustrates the methodology employed in the present study.  
After baseline quantitative sensory testing (QST) was completed, capsaicin 1% 
topical cream was applied to the tongue to induce burning pain.  Two minutes after 
the application of capsaicin, the capsaicin was removed and the mouth was rinsed 
with either GABA (0.5 M, or 0.05M), 1% lidocaine or water for 2 minutes.   
 
Figure 2:  A. The median intensity of capsaicin evoked burning pain is shown in the 
line drawing.  Rinsing with any solution reduced capsaicin evoked pain, however, 
compared with water pain resolved more rapidly after administration of GABA or 
lidocaine.  B. The bar graph illustrates the normalized median area under the VAS 
curve (VASAUC) post rinse for all 4 treatments for all 30 subjects.  Lines indicate the 
interquartile range.  All treatments were significantly better than water in reducing 
24 
 
capsaicin induced pain.  There was an apparent dose-related for response for GABA, 
whereby the higher concentration of GABA was somewhat better at reducing 
VASAUC than the lower concentration. *: P < 0.05, repeated measures ANOVA and 
Dunnett’s method compared with water 
 
Figure 3:  The line and scatter plots illustrate the effect of capsacin as well as the 
effect of the rinse solutions on A. cold detection threshold (CDT), B. warm detection 
threshold (WDT, and C. heat pain threshold (HPT).  Application of capsaicin 
significantly increaseed CDT and decresed WDT as well as HPT on the tongue.  In A, 
none of the treatments significantly altered the lowering of the cold detection threshold 
by capsaicin.  In B, rinsing with either GABA solution or lidocaine significantly 
reversed the capsaicin-induced reduction in warm detection.  Similarly, in C, rinsing 
with either GABA solution or lidocaine significantly reversed the capsaicin induced 
reduction in heat pain threshold.  Each circle is the mean from 30 subjects.  Error 
bars indicate standard error of the mean (SEM).  #: P < 0.05 repeated measures 
ANOVA and Student-Neuman Keuls method for time.  *: P < 0.05 repeated measures 
ANOVA and Student-Neuman Keuls method for treatment compared to water. 
 
Figure 4:  The line and scatter plots illustrate the effect of capsacin as well as the 
effect of the rinse solutions on A. MDT and B. MPT.  Application of capsaicin 
significantly increased MDT and significantly lowered MPT.  In A, none of the 
treatments significantly altered the increase in MDT by capsaicin.  In B, all the 
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treatments significantly reversed the capsaicin induced reduction in MPT.  Each 
circle is the mean from 30 subjects.  Error bars indicate standard error of the mean 
(SEM).  #: P < 0.05 repeated measures ANOVA and Student-Neuman Keuls method 
for time. 
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